Supplemental Figure 1: **Effect of CBO-P11 on Akt and NOS-2:** Mice treated with bleomycin (1 U/kg) in the presence or absence of CBO-P11 (0.3 mg/kg) or equal volumes of saline as control were euthanized at 28 days. **A.** Lung homogenate from treated mice was analyzed for pAkt and total Akt levels by Western blotting. **B.** Lung homogenate from treated mice was analyzed for NOS-2 levels by Western blotting. Blots were reprobed with β-actin antibody to confirm equal loading of the samples. The immunoblot signals were quantified by densitometry. Plots are mean ± S.E.M (n = 3).

Supplemental Figure 2: **Effect of PI3K inhibitors on NO: A.** CRL-1490 cells were left untreated or were treated with bleomycin (10 mU/ml) in the presence or absence of either LY294002 (10 μM) or Wortmannin (10 μM) for 1 h and analyzed for DAF fluorescence. Plots show relative fluorescence intensity over non-treated control. **B.** CRL-1490 cells were left untreated or were treated with bleomycin (10 mU/ml) in the presence or absence of either LY294002 (10 μM) or Wortmannin (10 μM) treated for 3 h and analyzed for NOS-2 levels by Western blotting. Blots were reprobed with β-actin antibody to confirm equal loading of the samples. The immunoblot signals were quantified by densitometry. Plots are mean ± S.E.M (n = 3).

Supplemental Figure 3: **Effect of CBO-P11 on CXCR 1/2: A.** Cells were either left untreated or pretreated with either AG (300 μM) or CBO-P11 (10 μM) for 1 h, followed by bleomycin treatment (10 mU/ml) for 24 h and CXCR 1/2 expression was determined by Western blotting. **B.** Mice treated with bleomycin (1 U/kg) in the presence or absence of CBO-P11 (0.3 mg/kg) or equal volumes of saline as control were euthanized at 28 days. Lung homogenate from treated mice was analyzed for CXCR 1/2 levels by Western blotting. All blots were reprobed with β-actin antibody to confirm equal loading of the samples. The immunoblot signals were quantified by densitometry. Plots are mean ± S.E.M (n = 4).

